Paper - WANFANG MED ONLINE

You Position: Home > Paper

Intervention therapy of MDS

( views:237, downloads:32 )

Author:: No author available

Journal Title:: CANCER RESEARCH AND CLINIC

Issue:: 3

DOI:: 10.3760/cma.j.issn.1006-9801.2006.03.001

Key Word:: 骨髓增生异常综合征;造血干细胞移植;干预性治疗

Abstract：骨髓增生异常综合征(MDS)为一组恶性克隆性造血干/祖细胞疾病,近年来有关MDS的治疗取得了较大的进展,包括免疫抑制剂治疗、化学治疗、造血干细胞移植以及抑制MDS克隆的药物治疗等,就MDS干预性治疗以及疗效作一概述.

Reference

[1]卢学春,朱宏丽,姚善谦,等.氨磷汀联合重组人红细胞生成素治疗高龄骨髓增生异常综合征近期疗效观察[J].2005,(3).
[2]曹星梅,张王刚,何爱利,等.沙利度胺联合治疗高危骨髓增生异常综合征及骨髓纤维化的疗效观察[J].2005,(2).
[3]刘新建,陈玲,王珊,等.三氧化二砷联合维甲酸治疗骨髓增生异常综合征[J].2004,(2).
[4]E, Musch,M, Malek,A, Chrissafidou.Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.[J].2003,82(4).
[5]Hugo, Castro-Malaspina,Richard E, Harris,James, Gajewski,etc.Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.[J].2002,99(6).
[6]Jun, Ooi,Tohru, Iseki,Satoshi, Takahashi,etc.Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome.[J].2003,101(12).
[7]van den Bosch J,Wijermans PW,Lubbert M,etc.The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes.[J].2004,28(8).
[8]M, Oosterveld,S, Suciu,G, Verhoef,etc.The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM[J].2003,17(5).
[9]Silverman LR,Demakos EP,Peterson BL,etc.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.[J].2002,20(10).
[10]R, Gologan,Daniela, Ostroveanu,Camelia, Dobrea,etc.Hypoplastic myelodysplastic syndrome transformed in acute myeloid leukemia after androgens and cyclosporin. A treatment.[J].2003,41(4).
[11]Appelbaum F,Gotlib J,Holmberg L,etc.Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.[J].2002,16(2).
[12]A F, List,F, Brasfield,R, Heaton,etc.Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.[J].1997,90(9).
[13]R, Kurzrock,J, Cortes,D A, Thomas,etc.Pilot study of low-dose interleukin-11 in patients with bone marrow failure.[J].2001,19(21).
[14]Wattel,Solary,Hecquet,etc.Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study[J].1998,102(4).
[15]Misgeld E,Germing U,Haas R,etc.Thalidomide for the treatment of patients with myelodysplastic syndromes.[J].2002,16(1).
[16]F, Roy-Peaud,M, Paccalin,G, Le Moal,etc.[Association of systemic diseases and myelodysplastic syndromes. A retrospective study of 14 cases].[J].2003,32(12).
[17]Kantarjian HM,Giles FJ,O'Brien SA,etc.Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.[J].2003,17(11).
[18]Gert J, Ossenkoppele,Wilfried J, Graveland,Pieter, Sonneveld,etc.The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.[J].2004,103(8).
[19]Deeg HJ,Scott B,Appelbaum FR,etc.Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.[J].2004,28(11).
[20]E, Hellstr?m-Lindberg.Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.[J].1995,89(1).
[21]Nemunaitis John,Rosenfeld Craig,Getty Laura,etc.Pentoxifylline and Ciprofloxacin in Patients with Myelodysplastic Syndrome[J].1995.
[22]E, Abraham,P F, Laterre,J, Garbino,etc.Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.[J].2001,29(3).
[23]Oosterveld M,Mandelli F,Selleslag D,etc.Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors.[J].2002,16(9).
[24]Gezer S,Reddy P,Chaudary NI,etc.Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.[J].2004,28(8).
[25]Bowen,Denzlinger,Brugger,etc.Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients[J].1998,103(3).
[26]T, de Witte,S, Suciu,G, Verhoef,etc.Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.[J].2001,98(8).